The Building Back Better Coalition, formed to support the proposals, has spent nearly $7 million on advertising this month, including an ad that says “C.E.O.s and Big Pharma” are “lying” to voters about Mr. Biden’s plan. The League of Conservation Voters, which spent nearly $6.7 million this month, is urging Congress to cut carbon pollution in half by 2030 — an element of the package — and has threatened to withhold campaign donations from Democrats who don’t support it.
Perhaps no aspect of the package has generated more lobbying activity than a proposal to lower the cost of prescription drugs by empowering Medicare to negotiate their cost. The pharmaceutical lobby is spending more than $1 million on television ads to oppose it. And there are now nearly 1,500 registered pharmaceutical or health care lobbyists working lawmakers in Congress, nearly three for every member, according to Open Secrets.
Ken Frazier, the executive chairman of Merck, which is helping fund the ads, conceded in a recent call with reporters that the companies are fighting the proposal so hard because they believe it will slash their revenue. But he also portrayed the lobbying push as altruistic, arguing that a decline in profit would lead to less money for research and development into new treatments and cures for diseases.
“We have looked at what this would be,” Mr. Frazier said. “We have modeled it, and our ability to fund R & D inside Merck will be reduced by almost half.”
PhRMA, the trade group representing pharmaceutical companies, launched its first ad against the package last month. In it, a woman named Sue looks into the camera, a tinge of melancholy in her voice, and says the Democrats’ plan would “make it harder for people on Medicare to get the medicines we need.” The ad airs frequently during political news shows watched by policymakers.
The association followed up that ad with another accusing politicians of wanting to decide “which medicines you can and can’t get, regardless of what your doctor prescribes.” That was followed with a print advertising campaign, and then an open letter from 30 pharmaceutical companies.
